204 related articles for article (PubMed ID: 26091081)
1. Tandem truncated rotavirus VP8* subunit protein with T cell epitope as non-replicating parenteral vaccine is highly immunogenic.
Wen X; Cao D; Jones RW; Hoshino Y; Yuan L
Hum Vaccin Immunother; 2015; 11(10):2483-9. PubMed ID: 26091081
[TBL] [Abstract][Full Text] [Related]
2. Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus ΔVP8* subunit parenteral vaccines.
Wen X; Wen K; Cao D; Li G; Jones RW; Li J; Szu S; Hoshino Y; Yuan L
Vaccine; 2014 Jul; 32(35):4420-4427. PubMed ID: 24962749
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates.
Wen X; Cao D; Jones RW; Li J; Szu S; Hoshino Y
Vaccine; 2012 Sep; 30(43):6121-6. PubMed ID: 22885016
[TBL] [Abstract][Full Text] [Related]
4. Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate.
Xue M; Yu L; Che Y; Lin H; Zeng Y; Fang M; Li T; Ge S; Xia N
Vaccine; 2015 May; 33(22):2606-13. PubMed ID: 25882173
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of porcine P[6], P[7]-specific △VP8* rotavirus subunit vaccines with a tetanus toxoid universal T cell epitope.
Wen X; Wei X; Ran X; Ni H; Cao S; Zhang Y
Vaccine; 2015 Aug; 33(36):4533-9. PubMed ID: 26192360
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model.
Xue M; Yu L; Jia L; Li Y; Zeng Y; Li T; Ge S; Xia N
Hum Vaccin Immunother; 2016 Nov; 12(11):2959-2968. PubMed ID: 27435429
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.
Fix AD; Harro C; McNeal M; Dally L; Flores J; Robertson G; Boslego JW; Cryz S
Vaccine; 2015 Jul; 33(31):3766-72. PubMed ID: 26065919
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
[TBL] [Abstract][Full Text] [Related]
9. Homotypic protection against rotavirus-induced diarrhea in infant mice breast-fed by dams immunized with the recombinant VP8* subunit of the VP4 capsid protein.
Gil MT; de Souza CO; Asensi M; Buesa J
Viral Immunol; 2000; 13(2):187-200. PubMed ID: 10892999
[TBL] [Abstract][Full Text] [Related]
10. Evolution of P[8], P[4], and P[6] VP8* genes of human rotaviruses globally reported during 1974 and 2017: possible implications for rotavirus vaccines in development.
Velasquez DE; Jiang B
Hum Vaccin Immunother; 2019; 15(12):3003-3008. PubMed ID: 31124743
[TBL] [Abstract][Full Text] [Related]
11. Recombinant bivalent subunit vaccine combining truncated VP4 from P[7] and P[23] induces protective immunity against prevalent porcine rotaviruses.
Tang X; Li S; Zhou J; Bian X; Wang J; Han N; Zhu X; Tao R; Wang W; Sun M; Li P; Zhang X; Li B
J Virol; 2024 May; 98(5):e0021224. PubMed ID: 38591886
[TBL] [Abstract][Full Text] [Related]
12. Genetic diversity of G1P[8] rotavirus VP7 and VP8* antigens in Finland over a 20-year period: No evidence for selection pressure by universal mass vaccination with RotaTeq® vaccine.
Hemming M; Vesikari T
Infect Genet Evol; 2013 Oct; 19():51-8. PubMed ID: 23831933
[TBL] [Abstract][Full Text] [Related]
13. Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant.
McAdams D; Lakatos K; Estrada M; Chen D; Plikaytis B; Sitrin R; White JA
J Immunol Methods; 2021 Jul; 494():113056. PubMed ID: 33857473
[TBL] [Abstract][Full Text] [Related]
14. Expression and characterization of a novel truncated rotavirus VP4 for the development of a recombinant rotavirus vaccine.
Li Y; Xue M; Yu L; Luo G; Yang H; Jia L; Zeng Y; Li T; Ge S; Xia N
Vaccine; 2018 Apr; 36(16):2086-2092. PubMed ID: 29555220
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens.
Agarwal S; Hickey JM; Sahni N; Toth RT; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
J Pharm Sci; 2020 Jan; 109(1):380-393. PubMed ID: 31400347
[TBL] [Abstract][Full Text] [Related]
16. Reverse Genetics Approach for Developing Rotavirus Vaccine Candidates Carrying VP4 and VP7 Genes Cloned from Clinical Isolates of Human Rotavirus.
Kanai Y; Onishi M; Kawagishi T; Pannacha P; Nurdin JA; Nouda R; Yamasaki M; Lusiany T; Khamrin P; Okitsu S; Hayakawa S; Ebina H; Ushijima H; Kobayashi T
J Virol; 2020 Dec; 95(2):. PubMed ID: 33087468
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and efficacy in mice of an adenovirus-based bicistronic rotavirus vaccine expressing NSP4 and VP7.
Xie L; Yan M; Wang X; Ye J; Mi K; Yan S; Niu X; Li H; Sun M
Virus Res; 2015 Dec; 210():298-307. PubMed ID: 26368053
[TBL] [Abstract][Full Text] [Related]
18. Design and testing of a highly conserved human rotavirus VP8* immunogenic peptide with potential for vaccine development.
Mohanty E; Dehury B; Satapathy AK; Dwibedi B
J Biotechnol; 2018 Sep; 281():48-60. PubMed ID: 29886031
[TBL] [Abstract][Full Text] [Related]
19. A Nanoparticle-Based Trivalent Vaccine Targeting the Glycan Binding VP8* Domains of Rotaviruses.
Xia M; Huang P; Jiang X; Tan M
Viruses; 2021 Jan; 13(1):. PubMed ID: 33419150
[TBL] [Abstract][Full Text] [Related]
20. A new rotavirus VP6-based foreign epitope presenting vector and immunoreactivity of VP4 epitope chimeric proteins.
Teng Y; Zhao B; Pan X; Wen Y; Chen Y
Viral Immunol; 2014 Apr; 27(3):96-104. PubMed ID: 24702286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
